GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

linerixibat   Click here for help

GtoPdb Ligand ID: 14439

Synonyms: compound 56 [PMID: 23678871] | GSK-2330672 | GSK2330672 | Lynavoy®
Approved drug
linerixibat is an approved drug
Compound class: Synthetic organic
Comment: Linerixibat (GSK2330672) is an oral ileal bile acid transporter (IBAT; ASBT; SLC10A2) inhibitor [7].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 4
Rotatable bonds 13
Topological polar surface area 150.41
Molecular weight 546.68
XLogP 2
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCCC[C@]1(CC)CS(=O)(=O)C2=CC(=C(C=C2[C@@H](C3=CC=CC=C3)N1)OC)CNC(CC(=O)O)CC(=O)O
Isomeric SMILES CCCC[C@]1(CC)CS(=O)(=O)C2=CC(CNC(CC(=O)O)CC(=O)O)=C(OC)C=C2[C@@H](C3=CC=CC=C3)N1
InChI InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
InChI Key CZGVOBIGEBDYTP-VSGBNLITSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Carreño F, Karatza E, Mehta R, Collins J, Austin D, Swift B. (2024)
Population Dose-Response-Time Analysis of Itch Reduction and Patient-Reported Tolerability Supports Phase III Dose Selection for Linerixibat.
Clin Pharmacol Ther, 115 (2): 288-298. [PMID:37953500]
2. Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Richards D, Storey J, Dukes G, Gilchrist K, Vallow S, Alexander GJ et al.. (2016)
BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
BMC Gastroenterol, 16 (1): 71. [PMID:27431238]
3. Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP et al.. (2017)
Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Lancet, 389 (10074): 1114-1123. [PMID:28187915]
4. Hirschfield GM, Bowlus CL, Jones DEJ, Kremer AE, Mayo MJ, Tanaka A, Andreone P, Jia J, Jin Q, Macías-Rodríguez RU et al.. (2026)
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Lancet Gastroenterol Hepatol, 11 (1): 22-33. [PMID:41173016]
5. Hirschfield GM, Kremer AE, Levy C. (2026)
Antipruritic effects of the ileal bile acid transporter inhibitor linerixibat.
Lancet Gastroenterol Hepatol, 11 (3): 182. [PMID:41690315]
6. Ino H, Endo A, Wakamatsu A, Ogura H, Numachi Y, Kendrick S. (2019)
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers.
Clin Pharmacol Drug Dev, 8 (1): 70-77. [PMID:29870578]
7. Wu Y, Aquino CJ, Cowan DJ, Anderson DL, Ambroso JL, Bishop MJ, Boros EE, Chen L, Cunningham A, Dobbins RL et al.. (2013)
Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes.
J Med Chem, 56 (12): 5094-114. [PMID:23678871]